The Motley Fool

3 ASX healthcare shares I would buy and hold for a decade

Over the last decade the healthcare sector has been a great place to invest your money.

During this time the S&P/ASX 200 Health Care index has almost quadrupled in value.

Whilst it is unlikely to repeat this incredible gain over the next decade, I believe it remains well-positioned to outperform the wider market due to a growing number of favourable tailwinds.

In light of this, I think owning a few healthcare shares could be a very good thing in 2020 and beyond.

Three that I would consider buying are listed below:

CSL Limited (ASX: CSL)

CSL is one of the world’s leading biotherapeutics companies. I continue to believe it would be a great long term option for investors due to the quality of its CSL Behring and Seqirus businesses. Both businesses look very well-positioned for long-term growth due to their leading products and lucrative development pipelines. In addition to this, in the near term, strong demand for immunoglobulins products and tight market conditions look set to underpin above-average growth.

Pro Medicus Limited (ASX: PME)

Another healthcare share to consider is Pro Medicus. It is a leading provider of a full range of radiology IT software and services to hospitals, imaging centres, and healthcare groups. In FY 2019 it delivered extremely strong earnings growth thanks to growing demand for its offering from a number of leading healthcare institutions. This led to it reporting a massive 91.9% increase in full year profit to $19.1 million. Given the quality of its products and its sizeable market opportunity, I believe Pro Medicus is capable of continuing this strong form for some time to come.

ResMed Inc. (ASX: RMD)

A third healthcare option to consider is ResMed. Thanks to its industry-leading sleep products, its fast-growing software solutions business, and the proliferation of sleep apnoea, I believe its shares could provide market-beating returns again over the next decade. Especially given its sizeable and growing addressable market. Management estimates that there are ~1 billion people impacted by sleep apnoea worldwide. The vast majority have not yet sought treatment.

NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading over 40% off it's high, all while offering a fully franked dividend yield over 3%...

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

CLICK HERE FOR YOUR FREE REPORT!

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended Pro Medicus Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.